Evidence map›Paper›PMID 41400859›Full record

ArticleVirchows Archiv : an international journal of pathology2026

GLI1-rearranged mesenchymal tumor of the ovary with a novel ACTG1::GLI1 fusion.

Xue Wang, Zilan Zhang, Xiaoqun Yang, Hongmei Yi, Huafeng Wang

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xue Wang *The Pathology Department of Ruijin Hospital Affiliated to School of Medicine, Shanghai Jiao Tong University, Huangpu District, Number 197, Ruijin 2 Road, Shanghai, China.
Zilan Zhang *Department of Pathology, Northern Jiangsu People's Hospital, Yangzhou, China.
Xiaoqun YangThe Pathology Department of Ruijin Hospital Affiliated to School of Medicine, Shanghai Jiao Tong University, Huangpu District, Number 197, Ruijin 2 Road, Shanghai, China.
Hongmei YiThe Pathology Department of Ruijin Hospital Affiliated to School of Medicine, Shanghai Jiao Tong University, Huangpu District, Number 197, Ruijin 2 Road, Shanghai, China. yidoctor@163.com.
Huafeng WangThe Pathology Department of Ruijin Hospital Affiliated to School of Medicine, Shanghai Jiao Tong University, Huangpu District, Number 197, Ruijin 2 Road, Shanghai, China. whf11679@rjh.com.cn.ORCID http://orcid.org/0009-0008-0306-9106

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here, we report an exceedingly rare case of a GLI1-rearranged mesenchymal neoplasm primarily occurring in the ovary, a highly unusual site for this tumor type, which typically arises in the gastrointestinal tract or soft tissues. The patient, a 17-year-old female, presented with acute abdominal pain, and imaging revealed an ovarian mass. Histopathological examination confirmed a GLI1-altered mesenchymal tumor, and RNA sequencing identified a novel ACTG1::GLI1 fusion, representing the first documented case of ACTG1 as a fusion partner for GLI1. By reviewing the literature, we further characterize the morphologic, immunophenotypic, and molecular genetic spectrum of this rare ovarian neoplasm, expanding the known diversity of GLI1-associated fusions in mesenchymal tumors.

Indexed as

Biomarkers, TumorGene FusionGene RearrangementOncogene Proteins, FusionOvarian NeoplasmsZinc Finger Protein GLI1AdolescentFemaleHumansBiomarkers, TumorGLI1 protein, humanOncogene Proteins, FusionZinc Finger Protein GLI1ACTG1::GLI1 fusionGLI1 rearrangementHedgehog signaling pathwayMesenchymal neoplasmOvarian tumor

Identifiers

PMID41400859

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.